BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Xu ZY, Wang XY, Liu CQ, Li YT, Zhuang FC. Decline in the risk of hepatitis A virus infection in China, a country with booming economy and changing lifestyles. J Viral Hepat. 2008;15 Suppl 2:33-37. [PMID: 18837831 DOI: 10.1111/j.1365-2893.2008.01026.x] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.1] [Reference Citation Analysis]
Number Citing Articles
1 Franco E, Meleleo C, Serino L, Sorbara D, Zaratti L. Hepatitis A: Epidemiology and prevention in developing countries. World J Hepatol 2012; 4(3): 68-73 [PMID: 22489258 DOI: 10.4254/wjh.v4.i3.68] [Cited by in Crossref: 157] [Cited by in F6Publishing: 112] [Article Influence: 15.7] [Reference Citation Analysis]
2 Wu JB, Li XL, Zhang J, Xu D, Zhu JJ, Zhou BS. Source identification through social networks in an epidemiological investigation of a hepatitis A outbreak at an elementary school in Anhui province, China. Epidemiol Infect 2014;142:1450-8. [PMID: 24047565 DOI: 10.1017/S0950268813002331] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
3 Fotouhi B, Shirkoohi MK. Temporal dynamics of connectivity and epidemic properties of growing networks. Phys Rev E 2016;93:012301. [PMID: 26871086 DOI: 10.1103/PhysRevE.93.012301] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
4 Chen Y, Zhang X, Zhao Y, Zhang Y, Wang S, Hao Z, Zhang Z, Ma J, Fang Y, Wang X. Waning of anti-HAV immunity in Shijiazhuang prefecture, Hebei province, China: A comparison of seroprevalence between 1992 and 2011. Vaccine 2014;32:6227-32. [DOI: 10.1016/j.vaccine.2014.09.022] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
5 Fangcheng Z, Xuanyi W, Mingding C, Liming J, Jie W, Qi J, Yuanping G, Wen Q, Yajuan X, Jiangsen M. Era of vaccination heralds a decline in incidence of hepatitis A in high-risk groups in China. Hepat Mon 2012;12:100-5. [PMID: 22509186 DOI: 10.5812/hepatmon.838] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.1] [Reference Citation Analysis]
6 Zhu Y, Yuan Z, Zhao Q, Chen G, Xu B. Seroprevalence of hepatitis A virus antibody in a population aged 0-30 years in Shanghai, China: implications for hepatitis A immunization. Epidemiol Infect 2013;141:556-62. [PMID: 22687628 DOI: 10.1017/S0950268812001161] [Cited by in Crossref: 7] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
7 Zhang ZL, Zhu XJ, Shan AL, Gao ZG, Zhang Y, Ding YX, Liu H, Wu WS, Liu Y, He HY, Xie XH, Xia WD, Li C, Xu WT, Li ZY, Lin HL, Fu WM. Effectiveness of 10-year vaccination (2001-2010) on Hepatitis A in Tianjin, China. Hum Vaccin Immunother 2014;10:1008-12. [PMID: 24503599 DOI: 10.4161/hv.27775] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
8 Shim JJ, Chin SO, Lee CK, Jang JY, Kim BH. Epidemiological changes in hepatitis A in Korea: increasing age and its effect on clinical outcomes. Epidemiol Infect 2012;140:2182-9. [DOI: 10.1017/s095026881200012x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
9 Zhang L, Wilson DP. Trends in notifiable infectious diseases in China: implications for surveillance and population health policy. PLoS One 2012;7:e31076. [PMID: 22359565 DOI: 10.1371/journal.pone.0031076] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 4.6] [Reference Citation Analysis]
10 Gomes MAC, Ferreira ADSP, Silva AAMD, Souza ERD. Hepatite A: soroprevalência e fatores associados em escolares de São Luís (MA), Brasil. Rev bras epidemiol 2011;14:548-55. [DOI: 10.1590/s1415-790x2011000400002] [Cited by in Crossref: 4] [Article Influence: 0.4] [Reference Citation Analysis]
11 Murphy TV, Feinstone SM, Bell BP. Hepatitis A vaccines. Vaccines. Elsevier; 2013. pp. 183-204. [DOI: 10.1016/b978-1-4557-0090-5.00008-2] [Cited by in Crossref: 9] [Article Influence: 1.0] [Reference Citation Analysis]
12 Wang Z, Chen Y, Xie S, Lv H. Changing Epidemiological Characteristics of Hepatitis A in Zhejiang Province, China: Increased Susceptibility in Adults. PLoS One 2016;11:e0153804. [PMID: 27093614 DOI: 10.1371/journal.pone.0153804] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.8] [Reference Citation Analysis]
13 Chen Y, Zhou CL, Zhang XJ, Hao ZY, Zhang YH, Wang SM, Ma JC, Zhao G, Qiu C, Zhao YL, Wang B, Wang XY. Immune memory at 17-years of follow-up of a single dose of live attenuated hepatitis A vaccine. Vaccine 2018;36:114-21. [PMID: 29183734 DOI: 10.1016/j.vaccine.2017.11.036] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
14 Xu ZY, Wang XY. Live attenuated hepatitis A vaccines developed in China. Hum Vaccin Immunother 2014;10:659-66. [PMID: 24280971 DOI: 10.4161/hv.27124] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.1] [Reference Citation Analysis]
15 Averhoff FM, Khudyakov Y, Nelson NP. Hepatitis A Vaccines. Plotkin's Vaccines. Elsevier; 2018. pp. 319-341.e15. [DOI: 10.1016/b978-0-323-35761-6.00024-9] [Cited by in Crossref: 6] [Article Influence: 1.5] [Reference Citation Analysis]
16 Hendrickx G, Van Herck K, Vorsters A, Wiersma S, Shapiro C, Andrus JK, Ropero AM, Shouval D, Ward W, Van Damme P. Has the time come to control hepatitis A globally? Matching prevention to the changing epidemiology. J Viral Hepat 2008;15 Suppl 2:1-15. [PMID: 18837827 DOI: 10.1111/j.1365-2893.2008.01022.x] [Cited by in Crossref: 49] [Cited by in F6Publishing: 45] [Article Influence: 3.5] [Reference Citation Analysis]